BLAINJECTIONINJECTABLE
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VEGZELMA (bevacizumab-adcd) by Celltrion is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2022.
Drug data last refreshed 2d ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEGZELMA is a bevacizumab-adcd biosimilar approved in September 2022 by Celltrion that inhibits vascular endothelial growth factor (VEGF) to block angiogenesis in cancer and ocular diseases. It is an antibody-drug conjugate (ADC) modality that functions as a VEGF-directed antibody, designed to match the efficacy and safety profile of reference bevacizumab. The product targets patients with VEGF-dependent solid tumors and retinal conditions who require anti-angiogenic therapy.
Peak
VEGZELMA is in peak commercial phase with moderate competitive pressure (30/100), indicating active market engagement and steady team investment for market penetration against established bevacizumab biosimilars.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VEGZELMA in peak lifecycle phase offers exposure to biosimilar competitive dynamics, payer negotiation strategies, and mature-market share defense—roles are primarily commercial rather than clinical innovation-focused. Career growth is dependent on volume achievement and market penetration execution against entrenched competitors rather than scientific advancement.
Brand Manager
Worked on VEGZELMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.